within Pharmacolibrary.Drugs.ATC.B;

model B01AX04
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 5.25e-06,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 5.9999999999999995e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>DermatanSulfate</td></tr><tr><td>ATC code:</td><td>B01AX04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dermatan sulfate is a glycosaminoglycan anticoagulant drug used in the prophylaxis and treatment of thromboembolic disorders. It enhances inhibition of thrombin and other coagulation factors. Dermatan sulfate is not currently approved by the FDA but has been used in some countries in the past. Its use is limited today, mainly replaced by heparins and direct oral anticoagulants.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for intravenous administration in adult patients, due to absence of published human PK data.</p><h4>References</h4><ol><li><p>Schuh, RS, et al., &amp; Ferreira Teixeira, H (2024). Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration. <i>International journal of pharmaceutics</i> 660 124355â€“None. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2024.124355\">10.1016/j.ijpharm.2024.124355</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38897489/\">https://pubmed.ncbi.nlm.nih.gov/38897489</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end B01AX04;
